

# Frank R Lichtenberg

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4843916/publications.pdf>

Version: 2024-02-01

79  
papers

2,093  
citations

304368

22  
h-index

264894

42  
g-index

80  
all docs

80  
docs citations

80  
times ranked

1168  
citing authors

#	ARTICLE	IF	CITATIONS
1	The association between pharmaceutical innovation and both premature mortality and hospital utilization in Switzerland, 1996â€“2019. Swiss Journal of Economics and Statistics, 2022, 158, .	0.5	0
2	The effect of pharmaceutical innovation on longevity: Evidence from the U.S. and 26 high-income countries. Economics and Human Biology, 2022, 46, 101124.	0.7	7
3	The effects of dynamic and static competition on prescription drug prices in Denmark, 1997â€“2017. Journal of Evolutionary Economics, 2022, 32, 1155-1173.	0.8	1
4	The impact of pharmaceutical innovation on the longevity and hospitalization of New Zealand cancer patients, 1998â€“2017. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 476-477.	0.7	0
5	Are drug prices subject to creative destruction? Evidence from the US, 1997â€“2017. Health Economics (United Kingdom), 2021, 30, 1910-1932.	0.8	5
6	Are patients more adherent to newer drugs?. Health Care Management Science, 2020, 23, 605-618.	1.5	4
7	How cost-effective are new cancer drugs in the U.S.?. Expert Review of Pharmacoeconomics and Outcomes Research, 2020, 20, 39-55.	0.7	9
8	The impact of pharmaceutical innovation on the burden of disease in Ireland, 2000â€“2015. Journal of Public Health, 2020, 42, 816-827.	1.0	3
9	The impact of pharmaceutical innovation on the burden of disease in Canada, 2000â€“2016. SSM - Population Health, 2019, 8, 100457.	1.3	7
10	The long-run impact of new medical ideas on cancer survival and mortality. Economics of Innovation and New Technology, 2019, 28, 722-740.	2.1	7
11	How many life-years have new drugs saved? A three-way fixed-effects analysis of 66 diseases in 27 countries, 2000â€“2013. International Health, 2019, 11, 403-416.	0.8	20
12	The impact of access to prescription drugs on disability in eleven European countries. Disability and Health Journal, 2019, 12, 375-386.	1.6	6
13	The Impact of Public and Private Research on Premature Cancer Mortality and Hospitalization in the United States, 1999-2013. American economist, The, 2018, 63, 147-165.	0.5	0
14	The Impact of New Drug Launches on Hospitalization in 2015 for 67 Medical Conditions in 15 OECD Countries: A Two-Way Fixed-Effects Analysis. Forum for Health Economics and Policy, 2018, 21, .	0.2	4
15	The Impact of New Drug Launches on Longevity Growth in Nine Middle Eastern and African Countries, 2007â€“2015. Review of Middle East Economics and Finance, 2018, 14, .	0.3	1
16	THE IMPACT OF NEW DRUG LAUNCHES ON LIFE-YEARS LOST IN 2015 FROM 19 TYPES OF CANCER IN 36 COUNTRIES. Journal of Demographic Economics, 2018, 84, 309-354.	1.2	10
17	The impact of pharmaceutical innovation on cancer mortality in Russia, 2001-2011. Journal of Pharmaceutical Health Services Research, 2018, 9, 79-89.	0.3	1
18	The Impact of Pharmaceutical Innovation on Cancer Mortality in Belgium, 2004â€“2012. Forum for Health Economics and Policy, 2017, 20, .	0.2	6

#	ARTICLE	IF	CITATIONS
19	The impact of pharmaceutical innovation on health outcomes and utilization in Turkey: A re-examination. <i>Health Policy and Technology</i> , 2017, 6, 226-233.	1.3	1
20	The Impact of Pharmaceutical Innovation on Premature Mortality, Hospital Separations, and Cancer Survival in Australia. <i>Economic Record</i> , 2017, 93, 353-378.	0.2	7
21	The impact of pharmaceutical innovation on cancer mortality in Mexico, 2003â€“2013. <i>Latin American Economic Review</i> , 2017, 26, .	0.3	4
22	The impact of pharmaceutical innovation on premature cancer mortality in Switzerland, 1995â€“2012. <i>European Journal of Health Economics</i> , 2016, 17, 833-854.	1.4	16
23	The impact of pharmaceutical innovation on premature cancer mortality in Canada, 2000â€“2011. <i>International Journal of Health Economics and Management</i> , 2015, 15, 339-359.	0.6	18
24	Pharmaceutical Innovation, Longevity, and Medical Expenditure in Greece, 1995â€“2010. <i>International Journal of the Economics of Business</i> , 2015, 22, 277-299.	1.0	2
25	The impact of recent chemotherapy innovation on the longevity of myeloma patients: US and international evidence. <i>Social Science and Medicine</i> , 2015, 130, 162-171.	1.8	11
26	The Impact of Pharmaceutical Innovation on Premature Mortality, Cancer Mortality, and Hospitalization in Slovenia, 1997â€“2010. <i>Applied Health Economics and Health Policy</i> , 2015, 13, 207-222.	1.0	8
27	The effect of pharmaceutical innovation on longevity, hospitalization and medical expenditure in Turkey, 1999â€“2010. <i>Health Policy</i> , 2014, 117, 361-373.	1.4	7
28	The impact of pharmaceutical innovation on longevity and medical expenditure in France, 2000â€“2009. <i>Economics and Human Biology</i> , 2014, 13, 107-127.	0.7	34
29	Pharmaceutical innovation and longevity growth in 30 developing and high-income countries, 2000â€“2009. <i>Health Policy and Technology</i> , 2014, 3, 36-58.	1.3	38
30	The impact of pharmaceutical innovation on longevity and medical expenditure in Sweden, 1997â€“2010: evidence from longitudinal, disease-level data. <i>Economics of Innovation and New Technology</i> , 2014, 23, 239-273.	2.1	13
31	The Impact of Pharmaceutical Innovation on Disability Days and the Use of Medical Services in the United States, 1997â€“2010. <i>Journal of Human Capital</i> , 2014, 8, 432-480.	0.6	28
32	The impact of therapeutic procedure innovation on hospital patient longevity: Evidence from Western Australia, 2000â€“2007. <i>Social Science and Medicine</i> , 2013, 77, 50-59.	1.8	14
33	The impact of new (orphan) drug approvals on premature mortality from rare diseases in the United States and France, 1999â€“2007. <i>European Journal of Health Economics</i> , 2013, 14, 41-56.	1.4	22
34	The Effect of Pharmaceutical Innovation on Longevity: Patient Level Evidence from the 1996â€“2002 Medical Expenditure Panel Survey and Linked Mortality Public-use Files. <i>Forum for Health Economics and Policy</i> , 2013, 16, 1-33.	0.2	22
35	Is Home Health Care a Substitute for Hospital Care?. <i>Home Health Care Services Quarterly</i> , 2012, 31, 84-109.	0.3	17
36	Contribution of Pharmaceutical Innovation to Longevity Growth in Germany and France, 2001â€“7. <i>Pharmacoeconomics</i> , 2012, 30, 197-211.	1.7	23

#	ARTICLE	IF	CITATIONS
37	The Effect of Pharmaceutical Innovation on the Functional Limitations of Elderly Americans: Evidence from the 2004 National Nursing Home Survey. <i>Advances in Health Economics and Health Services Research</i> , 2012, 23, 73-101.	0.2	5
38	Does competition stimulate drug utilization? The impact of changes in market structure on US drug prices, marketing and utilization. <i>International Review of Law and Economics</i> , 2012, 32, 95-109.	0.5	11
39	Has Pharmaceutical Innovation Reduced Social Security Disability Growth?. <i>International Journal of the Economics of Business</i> , 2011, 18, 293-316.	1.0	5
40	Despite steep costs, payments for new cancer drugs make economic sense. <i>Nature Medicine</i> , 2011, 17, 244-244.	15.2	10
41	The quality of medical care, behavioral risk factors, and longevity growth. <i>International Journal of Health Care Finance and Economics</i> , 2011, 11, 1-34.	1.2	44
42	What Are The Respective Roles Of The Public And Private Sectors In Pharmaceutical Innovation?. <i>Health Affairs</i> , 2011, 30, 332-339.	2.5	135
43	Pharmaceutical Companies'™ Variation Of Drug Prices Within And Among Countries Can Improve Long-Term Social Well-Being. <i>Health Affairs</i> , 2011, 30, 1539-1544.	2.5	12
44	The effect of drug vintage on survival: Micro evidence from Puerto Rico's Medicaid program. <i>Advances in Health Economics and Health Services Research</i> , 2010, 22, 273-292.	0.2	2
45	Pharmaceutical Price Discrimination and Social Welfare. <i>Capitalism and Society</i> , 2010, 5, .	0.3	9
46	Have newer cardiovascular drugs reduced hospitalization? Evidence from longitudinal country-level data on 20 OECD countries, 1995-2003. <i>Health Economics (United Kingdom)</i> , 2009, 18, 519-534.	0.8	25
47	Do New Drugs Save Lives?. <i>Journal of General Internal Medicine</i> , 2009, 24, 1356-1356.	1.3	1
48	The Impact of Drug Vintage on Patient Survival: A Patient-Level Analysis Using Quebec's Provincial Health Plan Data. <i>Value in Health</i> , 2009, 12, 847-856.	0.1	12
49	Life-expectancy gains from pharmaceutical drugs: a critical appraisal of the literature. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2009, 9, 499-504.	0.7	2
50	The effect of new cancer drug approvals on the life expectancy of American cancer patients, 1978-2004. <i>Economics of Innovation and New Technology</i> , 2009, 18, 407-428.	2.1	32
51	Pharmaceutical innovation and the longevity of Australians: A first look. <i>Advances in Health Economics and Health Services Research</i> , 2008, 19, 95-117.	0.2	11
52	Effects Of New Drugs On Overall Health Spending: Frank Lichtenberg Responds. <i>Health Affairs</i> , 2007, 26, 887-890.	2.5	14
53	IMPORTATION AND INNOVATION. <i>Economics of Innovation and New Technology</i> , 2007, 16, 403-417.	2.1	9
54	The Impact Of Medicare Part D On Prescription Drug Use By The Elderly. <i>Health Affairs</i> , 2007, 26, 1735-1744.	2.5	185

#	ARTICLE	IF	CITATIONS
55	The Impact of New Drugs on US Longevity and Medical Expenditure, 1990â€“2003: Evidence from Longitudinal, Disease-Level Data. <i>American Economic Review</i> , 2007, 97, 438-443.	4.0	49
56	Pharmaceutical-embodied technical progress, longevity, and quality of life: drugs as â€œEquipment for Your Healthâ€™. <i>Managerial and Decision Economics</i> , 2007, 28, 371-392.	1.3	28
57	Benefits and costs of newer drugs: an update. <i>Managerial and Decision Economics</i> , 2007, 28, 485-490.	1.3	18
58	The Effect of Using Newer Drugs on Admissions of Elderly Americans to Hospitals and Nursing Homes: State-level Evidence from 1997 to 2003. <i>Pharmacoeconomics</i> , 2006, 24, 5-25.	1.7	38
59	On â€œNew Cardiovascular Drugs: Patterns of Use and Association with Non-Drug Health Expendituresâ€• Inquiry (United States), 2006, 43, 80-82.	0.5	5
60	The impact of increased utilization of HIV drugs on longevity and medical expenditure: an assessment based on aggregate US time-series data. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2006, 6, 425-436.	0.7	17
61	Availability of New Drugs and Americans??? Ability to Work. <i>Journal of Occupational and Environmental Medicine</i> , 2005, 47, 373-380.	0.9	24
62	The Impact of New Drug Launches on Longevity: Evidence from Longitudinal, Disease-Level Data from 52 Countries, 1982?2001. <i>International Journal of Health Care Finance and Economics</i> , 2005, 5, 47-73.	1.2	118
63	Pharmaceutical Innovation and the Burden of Disease in Developing and Developed Countries. <i>Journal of Medicine and Philosophy</i> , 2005, 30, 663-690.	0.4	35
64	The effect of access restrictions on the vintage of drugs used by Medicaid enrollees. <i>American Journal of Managed Care</i> , 2005, 11 Spec No, SP7-13.	0.8	7
65	Sources of U.S. longevity increase, 1960â€“2001. <i>Quarterly Review of Economics and Finance</i> , 2004, 44, 369-389.	1.5	65
66	The effect of new drug approvals on HIV mortality in the US, 1987â€“1998. <i>Economics and Human Biology</i> , 2003, 1, 259-266.	0.7	24
67	The economic and human impact of new drugs. <i>Journal of Clinical Psychiatry</i> , 2003, 64 Suppl 17, 15-8.	1.1	0
68	Are The Benefits Of Newer Drugs Worth Their Cost? Evidence From The 1996 MEPS. <i>Health Affairs</i> , 2001, 20, 241-251.	2.5	167
69	Computer Use and Productivity Growth in US Federal Government Agencies, 1987â€“92. <i>Journal of Industrial Economics</i> , 1998, 46, 257-279.	0.6	69
70	The Output Contributions Of Computer Equipment And Personnel: A Firm-Level Analysis. <i>Economics of Innovation and New Technology</i> , 1995, 3, 201-218.	2.1	285
71	Ownership structure and corporate performance in Japan. <i>Japan and the World Economy</i> , 1994, 6, 239-261.	0.4	100
72	The Age Of Technology And Its Impact On Employee Wages. <i>Economics of Innovation and New Technology</i> , 1991, 1, 215-231.	2.1	27

#	ARTICLE	IF	CITATIONS
73	Aggregation of Variables in Least-Squares Regression. <i>American Statistician</i> , 1990, 44, 169-171.	0.9	9
74	Errors of Measurement in Output Deflators. <i>Journal of Business and Economic Statistics</i> , 1989, 7, 1-9.	1.8	33
75	Energy prices and induced innovation. <i>Research Policy</i> , 1986, 15, 67-75.	3.3	32
76	Pharmaceutical innovation as a process of creative destruction. , 0, , 21-72.		4
77	Spurious Correlation in Estimation of the Health Production Function: A Note. <i>SSRN Electronic Journal</i> , 0, , .	0.4	5
78	Pharmaceutical Knowledge-Capital Accumulation and Longevity. , 0, , 237-269.		17
79	Response to Baker and Fugh-Berman's Critique of My Paper, 'Why Has Longevity Increased More in Some States than in Others?'. <i>SSRN Electronic Journal</i> , 0, , .	0.4	17